MIPSS70+ scoring

Current understanding

Enhanced MIPSS70 incorporating cytogenetic risk. Refines high vs very-high-risk distinction.

2026-10-07 — Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.: Observational CALR-MPN cohort data suggest the current MIPSS70-plus v2.0 HMR panel under-captures risk in CALR-mutated disease, with KRAS and RUNX1 (alongside TP53) independently worsening LFS/OS and arguing for an expanded HMR definition in this subgroup. (novelty: 3)
2026-09-19 — Clinicopathologic Characteristics of SomaticMutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.: cross-connection with tp53-mutations-mpn-transplant-risk: MIPSS70+ already incorporates high-molecular-risk mutations but does not resolve TP53 single- vs multi-hit; the phase-dependent OS gradient shown here argues for augmenting molecular scoring with TP53 allelic status in chronic-phase MF. (novelty: 3)
2026-07-01 — Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.: cross-connection with mysec-mpm-kmpm: Both integrate high-risk mutations (ASXL1, U2AF1, SRSF2, TP53) and cytogenetics into risk scoring, but MYSEC-mPM/kmPM are specific to post-PV/post-ET MF whereas MIPSS70+ targets primary MF. (novelty: 3)